With the continuous efforts to eradicate the prevalence of HIV across the globe, a team of researchers have recently found that there is a certain type of new generation antibody that could most likely be essential for the fight against the said disease. These antibodies are said to be highly potent and is known to have the ability to effectively neutralize a large number of different HIV strains. In line with this, experts from the Rockefeller University in New York and Prof Florian Klein, University Hospital Cologne and German Center for Infection Research (DZIF), has recently tested a new HIV neutralizing antibody, called 10-1074, in humans and turned out to be successful.
Hope For HIV: 10-1074
In one of their statements reported by Science Daily, Prof Klein said that the broadly neutralizing antibody 10-1074 allegedly targets a specific structure known as V3 loop which is present on the HIV envelope protein. In the course of their study, the investigators have highly emphasized that the antibody has well tolerated and demonstrated favorable pharmacokinetic properties. It was found that the antibody showed high antiviral activity in the participants with HIV infection. One of the first authors of the study, Dr. Henning Gruell, has also claimed that they have performed series of comprehensive HIV sequence analysis in order to investigate the dynamics and mechanisms that the virus uses to escape the selection pressure by the antibody.
Future Plans For HIV Cure
Furthermore, according to EurekAlert, the team was apparently able to specifically investigate the development of resistant HIV variants. It was found the scientists are planning further trials to investigate an antibody-mediated treatment approach in patients with HIV infection. Experts said that a series of clinical trials have already been scheduled for spring with the hope of continuously eradicating the disease and to increase awareness. Ultimately, the experts note that the research wouldn't be possible if wasn't because of the collaborative efforts of Rockefeller University and many other clinical and scientific partners.
